Takeaways: The main market signal is strategic rather than commercial: Health Canada’s clearance, alongside PHAC’s collaboration with Moderna, helps de-risk the company’s mRNA infectious-disease...
Takeaways: Health Canada’s go‑ahead for Devonian’s seamless Phase II/III pediatric Thykamine program positions the company to enter a crowded but fast‑growing non‑steroidal topica...
Takeaways Skyhawk’s global Phase 2/3 FALCON-HD program for SKY-0515 positions the company as a front-runner in disease‑modifying treatment for Huntington’s disease, and if successful, a once‑dai...
